BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 16953186)

  • 1. In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands.
    Cascio MG; Bisogno T; Palazzo E; Thomas A; van der Stelt M; Brizzi A; de Novellis V; Marabese I; Ross R; van de Doelen T; Brizzi V; Pertwee R; Maione S; Di Marzo V
    Br J Pharmacol; 2006 Oct; 149(4):431-40. PubMed ID: 16953186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors.
    Marini P; Cascio MG; King A; Pertwee RG; Ross RA
    Br J Pharmacol; 2013 Jun; 169(4):887-99. PubMed ID: 23711022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
    Xu JJ; Diaz P; Astruc-Diaz F; Craig S; Munoz E; Naguib M
    Anesth Analg; 2010 Jul; 111(1):99-109. PubMed ID: 20522703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors.
    Govaerts SJ; Muccioli GG; Hermans E; Lambert DM
    Eur J Pharmacol; 2004 Jul; 495(1):43-53. PubMed ID: 15219819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.
    Shoemaker JL; Joseph BK; Ruckle MB; Mayeux PR; Prather PL
    J Pharmacol Exp Ther; 2005 Aug; 314(2):868-75. PubMed ID: 15901805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice.
    Bolognini D; Costa B; Maione S; Comelli F; Marini P; Di Marzo V; Parolaro D; Ross RA; Gauson LA; Cascio MG; Pertwee RG
    Br J Pharmacol; 2010 Jun; 160(3):677-87. PubMed ID: 20590571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists.
    Cascio MG; Bolognini D; Pertwee RG; Palazzo E; Corelli F; Pasquini S; Di Marzo V; Maione S
    Pharmacol Res; 2010 Apr; 61(4):349-54. PubMed ID: 19961936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.
    Pertwee RG; Thomas A; Stevenson LA; Ross RA; Varvel SA; Lichtman AH; Martin BR; Razdan RK
    Br J Pharmacol; 2007 Mar; 150(5):586-94. PubMed ID: 17245367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
    Brizzi A; Aiello F; Marini P; Cascio MG; Corelli F; Brizzi V; De Petrocellis L; Ligresti A; Luongo L; Lamponi S; Maione S; Pertwee RG; Di Marzo V
    Bioorg Med Chem; 2014 Sep; 22(17):4770-83. PubMed ID: 25065940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor.
    Chen RZ; Frassetto A; Lao JZ; Huang RR; Xiao JC; Clements MJ; Walsh TF; Hale JJ; Wang J; Tong X; Fong TM
    Eur J Pharmacol; 2008 Apr; 584(2-3):338-42. PubMed ID: 18336811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells.
    Gkoumassi E; Dekkers BG; Dröge MJ; Elzinga CR; Schmidt M; Meurs H; Zaagsma J; Nelemans SA
    Br J Pharmacol; 2007 Aug; 151(7):1041-8. PubMed ID: 17558435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.
    Ross RA; Brockie HC; Stevenson LA; Murphy VL; Templeton F; Makriyannis A; Pertwee RG
    Br J Pharmacol; 1999 Feb; 126(3):665-72. PubMed ID: 10188977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor.
    Olianas MC; Maullu C; Onali P
    Br J Pharmacol; 1997 Oct; 122(3):401-8. PubMed ID: 9351494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.
    Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG
    Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models.
    Naguib M; Diaz P; Xu JJ; Astruc-Diaz F; Craig S; Vivas-Mejia P; Brown DL
    Br J Pharmacol; 2008 Dec; 155(7):1104-16. PubMed ID: 18846037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties.
    Pertwee RG; Gibson TM; Stevenson LA; Ross RA; Banner WK; Saha B; Razdan RK; Martin BR
    Br J Pharmacol; 2000 Apr; 129(8):1577-84. PubMed ID: 10780961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity.
    Zádor F; Kocsis D; Borsodi A; Benyhe S
    Neurochem Int; 2014 Feb; 67():14-22. PubMed ID: 24508403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
    Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
    J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural determinants in the second intracellular loop of the human cannabinoid CB1 receptor mediate selective coupling to G(s) and G(i).
    Chen XP; Yang W; Fan Y; Luo JS; Hong K; Wang Z; Yan JF; Chen X; Lu JX; Benovic JL; Zhou NM
    Br J Pharmacol; 2010 Dec; 161(8):1817-34. PubMed ID: 20735408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi/o function.
    Eldeeb K; Leone-Kabler S; Howlett AC
    J Basic Clin Physiol Pharmacol; 2016 May; 27(3):311-22. PubMed ID: 27089415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.